SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report third quarter 2021 financial results and provide a corporate update after the market close on Wednesday, November 10, 2021. Management will host a conference call and webcast to review the results and provide an operational update.

Conference Call and Webcast Details:


Wednesday, November 10th @ 5:00 pm EST / 2:00 pm PST

Domestic: 844-358-9116

International: 209-905-5951

Conference ID: 9134928

Webcast:


http://investors.atyrpharma.com/events-and-webcasts

Abo


ut aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit

.

Contact:


Ashlee Dunston

Director, Investor Relations and Corporate Communications


[email protected]